The AZURE translational study

Exercise benefit to lifespan may be due to stem cell increase

Diagnosis of blood cancer after a breast cancer diagnosis

Histone deacetylases targeted as new strategy against graft versus host disease

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibition

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant

A need for clarity in clinical trial end points

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

Uncovering new targets for treatment of chronic lymphocytic leukaemia

Neratinib shows beneficial effects in the treatment of HER2 mutated breast cancer

Adjuvant chemotherapy for locally recurrent breast cancer